TAIWAN LIPOSOME/S (NASDAQ:TLC) has earned a consensus recommendation of “Buy” from the six analysts that are presently covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued a report on the stock in the last year is $8.92.
A number of analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of TAIWAN LIPOSOME/S in a research report on Wednesday, October 23rd. Cantor Fitzgerald restated an “overweight” rating on shares of TAIWAN LIPOSOME/S in a research report on Friday, October 18th. Finally, Zacks Investment Research raised TAIWAN LIPOSOME/S from a “hold” rating to a “buy” rating and set a $5.75 target price on the stock in a research note on Saturday, October 26th.
Shares of TLC stock traded down $0.03 during trading hours on Friday, reaching $5.05. 800 shares of the stock were exchanged, compared to its average volume of 722. The firm has a market capitalization of $162.66 million and a price-to-earnings ratio of -10.74. TAIWAN LIPOSOME/S has a 12-month low of $4.61 and a 12-month high of $11.00. The company’s 50-day moving average price is $5.08 and its 200-day moving average price is $5.26. The company has a current ratio of 2.69, a quick ratio of 2.69 and a debt-to-equity ratio of 0.73.
TAIWAN LIPOSOME/S Company Profile
Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.
Further Reading: What is the Difference Between Common Shares and Convertible Shares?
Receive News & Ratings for TAIWAN LIPOSOME/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TAIWAN LIPOSOME/S and related companies with MarketBeat.com's FREE daily email newsletter.